ARGX — ARGENX SE
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1697862 ·
Belgium
Last close
$876.00
Market Cap
$54.80B
52W High
$953.58
52W Low
$775.62
ADV30
293,584
Next earnings
2026-10-22
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 1,515,000,000 | 1,370,000,000 | 494,000,000 | 472,000,000 | 10,032,000,000 | 3,584,000,000 | 1,615,000,000 |
| Mar 2026 | 1,298,000,000 | 1,177,000,000 | 394,000,000 | 366,000,000 | — | — | — |
| Dec 2025 | 1,287,877,000 | 1,138,190,000 | 359,557,000 | 532,950,000 | 8,682,698,000 | 3,491,289,000 | 1,359,606,000 |
| Sep 2025 | 1,126,961,000 | 1,017,535,000 | 349,970,000 | 344,258,000 | — | — | — |
Balance + Analyst (yfinance extras)
Retained Earnings
$558,000,000
Inventory
$371,000,000
Receivables
$1,941,000,000
ST Investments
$1,600,000,000
EBIT TTM
$1,751,168,000
Pretax Income TTM
$1,747,347,000
Interest Exp TTM
$3,821,000
Analysts
23
Yahoo Snapshot (yfinance, live)
Total Revenue
$5,315,468,800
EBITDA
$1,612,902,016
Free Cash Flow
$761,769,024
Enterprise Value
$1,364,443,529,216
Total Cash
$5,184,000,000
Total Debt
$47,000,000
Shares Out
62,560,993
Trailing EPS
$26.63
Book Value
$5.38
ROE
23.6%
ROA
11.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 4,153,482,000 | 1,054,615,000 | 1,292,035,000 | 8,682,698,000 | 1,359,606,000 | — | 685,192,000 |
| Dec 2024 | 2,190,231,000 | -17,844,000 | 833,040,000 | 6,202,522,000 | 704,239,000 | — | -82,747,000 |
| Dec 2023 | 1,226,316,000 | -420,638,000 | -295,053,000 | 4,542,458,000 | 444,951,000 | — | -420,327,000 |
| Dec 2022 | 410,746,000 | -723,919,000 | -709,594,000 | 3,134,261,000 | 320,562,000 | — | -862,807,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$39.56
Max Pain — expiry 2026-08-21
max pain strike: $910.00 · spot: $856.94 · call oi: 1,317 · put oi: 1,070
Expected Move to 2026-08-21:
±$43.45
(5.07%) —
implied range
$813.49 –
$900.39
· ATM straddle on $860.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| RVMD | Revolution Medicines, Inc. | $43.99B | $205.26 | — |
| BIIB | BIOGEN INC. | $30.86B | $208.87 | — |
| MRNA | Moderna, Inc. | $25.42B | $63.67 | — |
| BNTX | BioNTech SE | $23.30B | $92.74 | — |
| GILD | GILEAD SCIENCES, INC. | $168.47B | $135.87 | — |
News headlines (Yahoo Finance, 1h cache)
argenx (ENXTBR:ARGX) Draws Fresh Valuation Debate, Is The Stock Overvalued Or Undervalued?
2026-08-11 16:13 · Yahoo
argenx (ENXTBR:ARGX) Stock Looks Fully Valued Despite Strong Returns And Deal Hopes
2026-08-11 11:11 · Yahoo
argenx (ENXTBR:ARGX) Is Considering A Forte Biosciences Acquisition
2026-08-10 22:11 · Yahoo
Forte Biosciences (FBRX) Agrees To argenx Takeover As Tender Offer Nears
2026-07-29 04:26 · Yahoo
European Equities Traded in the US as American Depositary Receipts Edge Up in Wednesday Trading
2026-08-05 15:12 · Yahoo
European Equities Traded in the US as American Depositary Receipts Decline in Monday Trading
2026-08-03 15:05 · Yahoo
European Equities Traded in the US as American Depositary Receipts Track Sharply Higher in Thursday Trading
2026-07-30 15:15 · Yahoo
Hedge Funds Favor argenx (ARGX) Over Forte Biosciences, Inc. (FBRX): Argenx Agrees to Buy Forte Biosciences
2026-08-11 18:35 · Yahoo
What Makes Argenx (ARGX) a New Buy Stock
2026-08-04 16:00 · Yahoo
Argenx SE (ARGX) Prepares to Demonstrate Vyvgart’s Efficacy in Broader Autoimmune Diseases
2026-08-04 15:35 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.